4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibition of Fatty Acid–Binding Protein 4 Attenuated Kidney Fibrosis by Mediating Macrophage-to-Myofibroblast Transition

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The macrophage-to-myofibroblast transition (MMT) process is an important pathway that contributing to renal interstitial fibrosis (RIF). Fatty acid–binding protein 4 (FABP4) deteriorated RIF via promoting inflammation in obstructive nephropathy. However, the clinical significance of FABP4 in fibrotic kidney disease remains to be determined and little is known of the FABP4 signaling in MMT. Biopsy specimens of chronic kidney disease patients and kidneys subjected to unilateral ureteral obstruction (UUO) of FABP4-deficient mice or FABP4 inhibitor-treated mice were collected for the investigation of FABP4 mediating MMT of RIF. We conducted kidney RNA-seq transcriptomes and TGF-β1-induced bone marrow–derived macrophage (BMDM) assays to determine the mechanisms of FABP4. We found that FABP4 expression correlated with RIF in biopsy specimens and the injured kidneys of UUO mice where FABP4 was co-expressed with MMT cells. In UUO mice, FABP4 deficiency and a highly selective FABP4 inhibitor BMS309403 treatment both suppressed RIF. FABP4 ablation also attenuated the UUO-induced number of MMT cells and serum amyloid A1 (Saa1) expression. The siRNA-mediated Saa1 knockdown decreased the number of MMT cells in vitro. In conclusion, FABP4 is an important factor contributing to RIF by mediating MMT, and genetic/pharmacological inhibition of FABP4 provides a novel approach for the treatment of kidney fibrosis.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

          Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD). All stages of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate prevalence data are lacking. Thus we sought to determine the prevalence of CKD globally, by stage, geographical location, gender and age. A systematic review and meta-analysis of observational studies estimating CKD prevalence in general populations was conducted through literature searches in 8 databases. We assessed pooled data using a random effects model. Of 5,842 potential articles, 100 studies of diverse quality were included, comprising 6,908,440 patients. Global mean(95%CI) CKD prevalence of 5 stages 13·4%(11·7–15·1%), and stages 3–5 was 10·6%(9·2–12·2%). Weighting by study quality did not affect prevalence estimates. CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3·5% (2·8–4·2%); Stage-2 (eGFR 60–89+ACR>30): 3·9% (2·7–5·3%); Stage-3 (eGFR 30–59): 7·6% (6·4–8·9%); Stage-4 = (eGFR 29–15): 0·4% (0·3–0·5%); and Stage-5 (eGFR<15): 0·1% (0·1–0·1%). CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3. Future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Acute-Phase Proteins and Other Systemic Responses to Inflammation

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Macrophages: versatile players in renal inflammation and fibrosis

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                30 September 2020
                2020
                : 11
                : 566535
                Affiliations
                [1] 1Division of Nephrology and National Clinical Research Center for Geriatrics, Kidney Research Institute, West China Hospital of Sichuan University , Chengdu, China
                [2] 2Core Facility of West China Hospital, Sichuan University , Chengdu, China
                [3] 3Laboratory of Clinical Pharmacy and Adverse Drug Reaction, West China Hospital of Sichuan University , Chengdu, China
                [4] 4Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital of Sichuan University , Chengdu, China
                Author notes

                Edited by: Guochang Hu, University of Illinois at Chicago, United States

                Reviewed by: David Nikolic-Paterson, Monash University, Australia; Xiao Wang, Ann & Robert H. Lurie Children’s Hospital of Chicago, United States

                *Correspondence: Liang Ma, liang_m@ 123456scu.edu.cn

                These authors have contributed equally to this work

                This article was submitted to Inflammation, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2020.566535
                7554244
                33101287
                b5f18ed3-d057-4568-82b0-0ed01870b84d
                Copyright © 2020 Feng, Guo, Xia, Liu, Mai, Liang, Zhu, Li, Bai, Li, Huang, Shi, Ma and Fu.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 29 May 2020
                : 07 September 2020
                Page count
                Figures: 6, Tables: 0, Equations: 0, References: 24, Pages: 12, Words: 0
                Categories
                Immunology
                Original Research

                Immunology
                kidney fibrosis,fatty acid–binding protein 4,macrophage-to-my ofibroblast transition,serum amyloid a1,renal interstitial fibrosis

                Comments

                Comment on this article